Phase 1/2 Clinical Trial: CoronaVac is safe and well tolerated in older adults. Neutralizing antibodies were detected in over 90% of participants in all groups

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases

Commentary: Inactivated COVID-19 vaccines to make a global impact – The Lancet Infectious Diseases

Commentary on Twitter

Second phase 1/2 trial published for Sinovac's CoronaVac, inactivated vaccine (both in China): the first was in adults to age 59. This one is 422 people aged 60+. Signs of immunity similar to the younger group, very low rate of adverse events https://t.co/ZQWknrK7Ry (No protocol)

— Hilda Bastian, PhD (@hildabast) February 4, 2021